Management of mantle cell lymphoma in the elderly: current and potential strategies.

about

New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma.

P2860

Q35951381-7C6F6553-B29E-4821-98C0-C7E6C41951A5 Q37520396-ED96EB94-E213-4426-8291-6EEDDB4F886D

P2860

Management of mantle cell lymphoma in the elderly: current and potential strategies.

Item

http://www.wikidata.org/entity/Q38157682

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of mantle cell lymphoma in the elderly: current and potential strategies.

@en

type

Item

label

Management of mantle cell lymphoma in the elderly: current and potential strategies.

@en

prefLabel

Management of mantle cell lymphoma in the elderly: current and potential strategies.

@en

P1476

Management of mantle cell lymphoma in the elderly: current and potential strategies.

@en

P2093

Marguerite Vignon

http://www.w3.org/2001/XMLSchema#string

Marie-Dominique Venon

http://www.w3.org/2001/XMLSchema#string

Richard Delarue

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

P2888

s40266-013-0129-1

P304

979-986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40266-013-0129-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24178346

http://www.w3.org/2001/XMLSchema#string

Management of mantle cell lymphoma in the elderly: current and potential strategies.

about

P2860

P2860

Management of mantle cell lymphoma in the elderly: current and potential strategies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698